<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (t-MN) include <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> arising in patients who have been treated with chemotherapy, radiation therapy, <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> or after documented exposure to environmental carcinogen </plain></SENT>
<SENT sid="1" pm="."><plain>t-MN are defined according to the primary treatment and the corresponding genetic and molecular lesions </plain></SENT>
<SENT sid="2" pm="."><plain>Chromosome(s) 7 and/or 5 <z:mp ids='MP_0004026'>monosomies</z:mp> or deletions are typical of <z:chebi fb="0" ids="22333">alkylating agent</z:chebi>-induced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, while balanced translocations involving chromosome bands 11q23 and 21q22 are associated to preceeding therapy with DNA-<z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="35221">Antimetabolites</z:chebi>, and in particular the <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> <z:chebi fb="2" ids="2948">azathioprine</z:chebi> and fludarabine, have also been recently associated to t-MN </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001909'>Leukemias</z:hpo> developing after <z:chebi fb="56" ids="16716">benzene</z:chebi> exposure are similar to t-MN and are characterized by chromosomal aberrations, which have been also observed among otherwise healthy <z:chebi fb="56" ids="16716">benzene</z:chebi>-exposed workers </plain></SENT>
<SENT sid="5" pm="."><plain>Individual predisposing factors, including polymorphisms of detoxification and DNA-repair enzymes have been identified </plain></SENT>
<SENT sid="6" pm="."><plain>Two genetic variants in key metabolizing enzymes, myeloperoxidase and <z:chebi fb="0" ids="13392">NAD(P)H</z:chebi>:<z:chebi fb="0" ids="36141">quinone</z:chebi> oxidoreductase, have been shown to influence susceptibility to <z:chebi fb="56" ids="16716">benzene</z:chebi> hematotoxicity </plain></SENT>
<SENT sid="7" pm="."><plain>Combination of polymorphisms impairing detoxification and DNA repair may significantly increase therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasm</z:hpo> risk </plain></SENT>
<SENT sid="8" pm="."><plain>Among <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, long-term survivors of Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are exposed to an increased t-MN risk, particularly when receiving MOPP-based and escalated-BEACOPP regimens, and when alkylators are combined to radiotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are at highest risk if total body irradiation followed by autologous stem cell transplantation is used as rescue or consolidation </plain></SENT>
<SENT sid="10" pm="."><plain>The addition of granulocyte-colony stimulating factor (G-CSF) and radiotherapy plays a significant role in t-MN following treatment of childhood <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>In <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, treatment for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:mpath ids='MPATH_310'>germ-cell tumors</z:mpath> has been associated with a 1-5% lifetime risk of t-MN </plain></SENT>
</text></document>